MICHAEL STEFAN, M.D.SOUTHERN OHIO MEDICAL CENTERSCIOTO COUNTY MEDICAL SOCIETY

2/19/10

MOLE OR MELANOMA: EARLY DETECTIONLIFETIME RISK FOR THE DEVELOPMENT OF

MELANOMA IS 1 IN 40 FOR 2010; UP FROM 1 IN 1500 IN THE 1935. ANNUAL NEW CASES ARE APPROXIMATELY 50,000.

IF SPREAD TO REGIONAL NODES ARE DISCOVERED, ONLY ONE THIRD WILL BE CURED.

ABCDE-A=ASYMMETRY; B=BORDER IRREGULARITY; C=COLOR VARIEGATION; D=DIAMETER >5MM AND E= ELEVATION. THE COMMON DENOMINATOR IS THEIR CHANGING NATURE WHICH SHOULD PROMPT EXCISIONAL BIOPSY.

HIGH VIGILANCE AND A LOW THRESHOLD FOR DERMATOLOGIC BIOPSY IS ESSENTIAL.

MOLES ARE A CLUSTER OF MELANOCYTES. MOST PEOPLE HAVE 10 – 40 MOLES.

2

A SIMPLE TOOL FOR EVALUATION OF MOLES.

3

GROWTH PATTERNS OF MELANOMA

SUPERFICIAL SPREADING MELANOMA = 70%NODULAR MELANOMA = 20%LENTIGO MALIGNA MELANOMA = 10% IN

ELDERLY POPULATION, MINIMAL PROPENSITY TO UNDERGO VERTICAL GROTH PHASE.

CONGENITAL NEVIAMELANOTIC MELANOMAUNKNOWN PRIMARY70% OF MELANOMAS FROM PRE-EXISTING

NEVUS.

4

HISTOLOGIC GROWTH PATTERNS OF MELANOMA: GROWTH PATTERNS; IMPORTANT BECAUSE THEY DETERMINE

PROGNOSIS AND ARE DIVIDED INTO 4 PATTERNS: 1. SSM 2. NM 3.LMM 4. ACRAL LENTIGINOUS MELANOMA (ALM). 70% OF MELANOMAS ARE SSM AND MOST ARISE IN A PRE-EXISTING NEVUS. NM ACCOUNTS FOR 15-30% AND FREQUENTLY EVOLVE DE NOVO, MORE COMMON IN MEN AND AXIAL. LMMS CONSTITUTE 5% AND HAVE A LOW PROPENSITY FOR METASTASIS AND ARE ON THE FACE IN ELDERLY INDIVIDUALS. . UNCOMMON BEFORE AGE 50. ALMS OCCUR ON THE PALMS AND SOLES AND NAILBEDS. THEY ARE MORE COMMON IN PHENOTYPES 3 AND 4 ( MEDITERRANIAN, LATIN AND AFRO-AMERICAN).WHILE ALM ARE RARE THEY ARE AGGRESSIVE.

BIOLOGY OF MELANOMA – LOCATED AT THE EPIDERMAL-DERMAL JUNCTION, ARE OF NEURAL CREST ORIGIN AND ARE LOCATED ON THE SKIN IN 90%. ABOUT 4% OF MELANOMAS HAVE NO KNOWN PRIMARY SITE. THE TECHNIQUE OF MOLECULAR GENETICS HAVE BEEN USED TO IDENTIFY THE GENE ENCODING TYRONINASE SPECIFICALLY EXPRESSED IN MELANOCYTES. HMB-45 AND S-100 ARE HISTOLOGICAL MARKERS USED TO I.D. MELANOMA.

5

FAMILIAL AND SYNDROMIC MELANOMA

FAMILIAL MELANOMAS ARE UNCOMMON BUT HAVE BEEN WELL DOCUMENTED . THIS IS A AUTOSOMAL DOMINANT TRANSMISSION ORIGINALLY TERMED THE B-K MOLE SYNDROME AND NOW REFERRED TO AS THE DYSPLASTIC NEVUS SYNDROME., FAMILIAL TYPE.

MELANOMA SUSCEPTIBILITY GENES. 90% ARE SPORADIC; 7% FAMILIAL AND 3% HEREDITARY, THE HEREDITARY TYPE IS THE CDNK2A (P16) GENE CONTROLLING CELL GROWTH.

6

7

8

9

10

METASATIC MELANOMA

LENTIGO MALIGNA MELANOMA

11

RISK FACTORS: CONGENITAL HAIRY NEVUS

12

MELANOMA RISK FACTORS

13

PHENOTYPE 1

14

PHENOTYPE 3

15

16

THE EPIDERMAL MELANIN UNIT

17

RISK FACTORS FOR MELANOMA : INTRINSIC

MELANOCYTE : MELANOSOME :SKINRETINAMUCOSAMENINGES

FOUND IN THE EPIDERMAL KERATINOCYTE

MSH-MELANIN STINULATING HORMONE DETERMINES PHENOTYPE OF PATIENT

FITZPATRICK PHENOTYPE IS CLASSIFIED FROM TYPE 1 THRU 5.

18

RISK FACTORS FOR MELANOMA : EXTRINSIC

19

PLUS

CUMULATIVE LIFETIME ULTRAVIOLET RADIATION

EQUALS

MELANOMA RISK

NOTE: GREATER THAN FIVE CHILDHOOD BURNS !

20

CUTANEOUS

MELANOMA

MELANOMA PROGRESSION PUTATIVE STEPS IN PROGRESSION FROM A NORMAL

MELANOCYTE TO MELANOMA: COMMON AQUIRED NEVUS…DYSPLASTIC NEVUS…INTRAEPITHELIAL PROLIFERATION OF ATYPICAL MELANOCYTES…MELANOMA IN SITU…SSM…VERTICAL GROWTH PHASE…METASTATIC

ONE OF THE BEST CHARECTERIZED GROWTH FACTORS FOR MELANOMA IS bFGF BASIC FIBROBLAST GROWTH FACTOR. SEVERAL MELANOMA CELL SURFACE MARKERS ARE PRESENT INCLUDING GANGLIOSIDE GD2

AT LEAST 4 DISTINCT GENES LOCATED ON CHROMOSOMES 1,6,7 AND 9 MAY PLAY A ROLE IN MELANOMA.POSSIBLY A COMPLEX SET OF GENETIC EVENTS. CYTOGENIC ANALYSIS OF MELANOMA COULD BE USEFUL IN PREDICTING CLINICAL COURSE.

EXPOSURE TO SUNLIGHT IS CONSIDERED THE MAJOR CAUSE OF MELANOMA. THE IMMUNE SYSTEM MAY BE DEPRESSED BY UVB RAYS. HOWEVER, CUMULATIVE SUN EXPOSURE DOES NOT EXPLAIN ALL OF THE BIOLOGIC BEHAVIOR OF MELANOMA. THE HIGHEST INCIDENCE OF MELANOMA IS IN QUEENSLAND, AUSTRALIA

21

MELANOMA: CLINICAL WORK-UPWORKUP: CXR AND CT/PET SCAN- BLOOD CHEMISTRIES.SERUM ALKALINE PHOSPHATASE AND LACTIC

DEHYDROGENASE-PERHAPS OF HISTORICAL INTEREST ONLY.

BRAIN CT OR MRIBONE SCANCONSULTATIONS BETWEEN ONCOLOGIST, RADIATION

THERAPIST, GENERAL SURGEON AND PLASTIC SURGEON. PROGNOSTIC FACTORS; BALCH 8500 PATIENTS

UNIVARIANT AND MULTIVARIANT ANALYSIS FOR STAGE 1 AND 2 PRODUCING A RELATIONSHIP BETWEEN TUMOR THICKNESS AND 10 YEAR MORTALITY.

FOLLOW-UP EVERY 6 MONTHS. RECURRENCE CAN OCCUR AS LATE AS 20 YEARS

FOLLOWING PRIMARY DIAGNOSIS.

22

MICROSTAGING: HISTORY

23

MELANOMA HISTORY

HISTORICALLY, THE FIRST PUBLISHED PATIENT WITH MELANOMA WAS BY JOHN HUNTER IN 1787. THE PATIENT WAS A 35 YEAR-OLD MALE.

RENE LAENNEC FIRST DESCRIBED MELANOMA AS A DISEASE ENTITY IN 1806. ( THEREFORE, NEARLY 200 YEARS OF UNDERSTANDING THE DISEASE.)

BIOLOGY, NATURAL HISTORY AND TREATMENTTHE CURRENT 5 YEAR SURVIVAL RATE OF 84%

REPRESENTS A MARKED IMPROVEMENT OVER THE 60% RATE FOR THE YEAR 1960.

DYSPLASTIC NEVI ARE LARGER (>6MM ) THAN COMMON MELANOCYTIC NEVI AND THEIR PRESENCE SUGGESTS AN INCREASED INCIDENCE OF MELANOMA, EITHER IN THE DYSPLASTIC NEVUS OR IN UNINVOLVED SKIN.

24

MELANOMA MICROSTAGINGA MALIGNANT TUMOR OF MELANOCYTES, CELLS THAT

ARE DERIVED FROM THE NEURAL CREST. PREDOMINANTLY OCCUR IN ADULTS. EARLY SIGNS IN A NEVUS INCLUDE DARKER OR

VARIABLE DISCOLORATION, INTERVAL INCREASE IN SIZE, NODULARITY AND SYMPTOMATOLOGY; ITCHING, ULCERATION OR BLEEDING.

EXCISIONAL BIOPSY IS REQUIRED. THERE IS NO ROLE FOR INCISIONAL BIOPSY OR SHAVE BIOPSY AND AN EXPERIENCED DERMATOPATHOLOGIST IS REQUIRED FOR PROPER MICROSTAGING.

PROGNOSIS IS AFFECTED BY CLINICAL AND HISTOLOGIC FACTORS.

HISTOLOGIC FEATURES; THICKNESS OR LEVEL OF INVASION, MITOTIC INDEX, PRESENCE OF TUMOR INFILTRATING LYMPHOCYTES, SATELITOSIS

25

26

MICROSTAGING

27

DISTINGUISHING BETWEEN A BENIGN PIGMENTED LESION AND EARLY MELANOMA CAN BE DIFFICULT, AND EVEN EXPERIENCED DERMATOPATHOLOGISTS CAN HAVE DIFFERING OPINIONS.

THE MICROSTAGE OF MELANOMA IS DETERMINED BY 2 CLASSIFICATIONS ON HISTOLOGIC EXAMINATION. THE VERTICAL THICKNESS (BRESLOW) AS MEASURED BY A MICROMETER AND THE LEVEL OF INVASION WITHIN THE VARIOUS DERMAL LAYERS ( CLARK).

PATHOLOGIC STAGING INCLUDES MICROSTAGING OF THE PRIMARY MELANOMA AND PATHOLOGIC INFORMATION REGARDING THE REGIONAL LYMPH NODES AFTER SENTINAL NODE BIOPSY AND/OR LYMPHADENECTOMY.

DISCUSSION REGARDING MICROSTAGING

MICROSTAGING:

28

29

CLARK AND BRESLOW CLASSIFICATIONS:

CLARK CLASSIFICATION BASED ON DEPTH OF PENETRATION INTO PAPPILARY AND RETICULAR DERMIS. A MELANOMA BECOMES MALIGNANT WHEN IT PENETRATES THE BASEMENT MEMBRANE. THE SPREAD OF MELANOMA OCCURS IN THE SUPERFICIAL SUBCUTANEOUS TISSUE WHERE THE LYMPHATIC DRAINAGE IS LOCATED.

BRESLOW CLASSIFICATION- LESS SUBJECTIVE, MICROMETER IS USED TO MEASURE FROM THE GRANULAR LAYER TO THE DEEPEST POINT OF PENETRATION OF TUMOR CELLS.

BOTH CLASSIFICATIONS ARE REPORTED IN PATHOLOGY REPORT.

30

MULTIVARIATE ANALYSIS OF MELANOMAMULTIFACTORIAL ANALYSIS-THICKNESS

OF MELANOMA, ULCERATION, ANATOMIC LOCATION APPEAR TO BE THE MOST IMPORTANT. SEX, AGE AND TUMOR CHARACTERISTICS ALSO IMPORTANT.

HISTOLOGIC TUMOR CHARACTERISTICS OF LYMPHOCYTE INVASION, MICROSCOPIC SATELLITES, MITOTIC ACTIVITY AND LEVEL OF INVASION.

31

SURGICAL THERAPY

32

EXCISIONAL BIOPSY

FOLLOWING EXCISIONAL BIOPSY, THIN MELANOMAS ( < .76 mm ) ARE SURGICALLY TREATED WITH A 1.0 CM RADIAL EXCISION MARGIN. INTERMEDIATE DEPTH LESIONS ( .75 TO 2.0 mm ) ARE TREATED WITH A 2.0 RADIAL EXCISION. SOMEWHAT CONTROVERSIAL, PRIMARY LESIONS 2.0 TO 4 mm CAN BE TREATED WITH A 2.0 CM RADIAL EXCISION. MORE RADICAL TREATMENT OF THE PRIMARY SITE PROBABLY DOES NOT CONFER A SURVIVAL ADVANTAGE. LESIONS GREATER THAN 4 mm REQUIRE EXCISIONAL BIOPSY ONLY AND FURTHER THERAPY IS AIMED AT SYSTEMIC CONTROL BASED ON THE HIGH PREVELANCE OF ESTABLISHED SYTEMIC METASTASIS

33

EXCISIONAL BIOPSY

34

SURGICAL TREATMENT

THE CORRECT SURGICAL TECHNIQUE FOR TREATMENT OF THE PRIMARY LESION INCLUDES A COMPOSITE RESECTION OF SKIN AND SUBCUTANEOUS FAT WITH PRESERVATION OF THE UNDERLYING FASCIA OR MUSCLE. REGARDLESS OF ANATOMIC LOCATION, FLAP RECONSTRUCTION OF THE POST-SURGICAL SITE IS PREFERRED. THERE IS NO ROLE FOR SKIN GRAFTING IN THIS REGARD.

PRIOR TO RESECTION OF THE PRIMARY LESION, ACCURATE IDENTIFICATION OF POTENTIALLY INVOLVED NODAL BASINS IS REQUIRED. LYMPHOSCINTIGRAPHY

MELANOMAS THAT HAVE A THICKNESS GREATER THAN 4.0 mm SHOULD BE CONSIDERED FOR ADJUVANT THERAPY WITH HIGH DOSE INTERFERON. TO DATE, THREE WELL DESIGNED PROSPECTIVE, RANDOMIZED CONTROLLED TRIALS DEMONSTRATED BOTH A DISEASE-FREE AND OVERALL SURVIVAL ADVANTAGE WITH INTERFERON WHEN COMPARED TO OBSERVATION OR ALTERNATE GANGLIOSIDE VACCINE.

ADJUNCTIVE CHEMOTHERAPY WITH MELPHALAN DOES NOT IMPROVE SURVIVAL . THE ONLY POTENTIAL DURABLE RESPONSE TO DISSEMINATED MELANOMA IS HIGH-DOSE INTERLEUKIN-2 (IL-2).

ALL PATIENTS WITH DISTANT METASTASIS ARE APPROPRIATELY CONSIDERED CANDIDATES FOR CLINICAL TRIALS EXPLORING NEW FORMS OF TREATMENT SUCH AS COMBINATION CHEMOTHERAPY, MONOCLONAL ANTIBODIES, IL-2, INTERFERONS, VACCINE IMMUNOTHERAPY AND BIOCHEMOTHERAPY.

35

WIDE LOCAL EXCISION OF AN INTERMEDIATE DEPTH MELANOMA:NOTE THE USE OF LYMPHAZURIN BLUE

36

SENTINAL LYMPH NODE MAPPING SPONTANEOUS REGRESSION OF MELANOMA IS SEEN IN LESS

THAN 1%. INTERMEDIATE THICKNESS IS >.75 TO 2mm IN DEPTH.

REGARDLESS OF THE BRESLOW DEPTH OF THE PRIMARY LESION IT IS SAFE TO SAY THAT ALL LESIONS CAN BE ADEQUATELY TREATED WITH A 2CM RADIAL MARGIN. ELECTIVE REGIONAL LYMPH NODE DISSECTION IS OF NO PROVEN BENEFIT IN STAGE 1 MELANOMA. HOWEVER, LYMPHATIC MAPPING AND SENTINAL LYMPH NODE BIOPSY FOR PATIENTS WHO HAVE TUMORS OF INTERMEDIATE THICKNESS MAY IDENTIFY THOSE PATIENTS WHO MAY BENEFIT FROM THERAPEUTIC LYMPHADENECTOMY.

ALTHOUGH PROPHYLACTIC REGIONAL LYMPH NODE DISSECTIONS HAVE BEEN USED IN PATIENTS WITH STAGE 11 MELANOMAS, 4 PROSPECTIVE RANDOMIZED TRIALS HAVE FAILED TO SHOW A SURVIVAL BENEFIT. IN FACT, TO DATE ELND AND TLND HAVE UNIVERSALLLY FAILED TO ABATE DISEASE PROGRESSION. FURTHERMORE, UNLIKE BREAST CANCER WHEREIN NODE DISSECTION IS OF VALUE FOR STAGING ONLY, RADICAL LYMPHADENECTOMY CARRIES A SIGNIFICANT OCCURRENCE OF PATIENT MORBIDITY.

37

SENTINAL LYMPH NODE MAPPING: GAMMA DETECTION

38

SENTINAL LYMPH NODE MAPPING

39

SENTINAL LYMPH NODE MAPPING

40

SAPPY’S LINE: OF HISTORICAL IMPORTANCE ONLY

41

THIS WILL IDENTIFY THE NODAL BASIN(S) THE MELANOMA IS DRAINING TO AND DIRECT THE SURGEON IN OBTAINING A SENTINAL NODE.FROZEN SECTION HISTOPATHOLOGY CANNOT BE PERFORMED ON THE PRIMARY LESION OR NODE.THE FALSE NEGATIVE RATE FOR SENTINAL NODE BIOPSY IS 3%.

42

43

SENTINAL LYMPH NODE BIOPSYTHE DIAGNOSTIC ACCURACY OF SENTINAL LYMPH NODE

BIOPSY (SLNB) HAS BEEN DEMONSTRATED IN SEVERAL STUDIES., WITH A FALSE NEGATIVE RATE <2%. USING A VITAL BLUE DYE AND A RADIOPHARMACEUTICAL AGENT INJECTED AT THE SITE OF THE PRIMARY TUMOR. THE FIRST LYMPH NODE THAT DRAINS THE NODAL BASIN CAN BE IDENTIFIED AND EXAMINED FOR MICROMETASTASIS. IF MICROMETASTASIS IS FOUND BY THE DERMATOPATHOLOGIST, ELND CAN BE PERFORMED. HOWEVER, THERE IS NO PROVEN SCIENTIFIC EVIDENCE THAT ELND IN THE SETTING OF MICROMETASTASIS WILL IMPROVE DISEASE FREE SURVIVAL. THESE PATIENTS MAY BENEFIT FROM INTERFERON THERAPY AND IT IS PERHAPS HERE, THAT SLNB IS OF VALUE.

THE OVERALL MEDIAN SURVIVAL FOR PATIENTS TREATED WITH HIGH DOSE INTERFERON WHEN COMPARED WITH CONTROLS IS 3.8 YEARS.

44

SENTINAL LYMPHADENECTOMY IN CUTANEOUS THIN MELANOMAS :

RICHARD BLEICHER, JOHN WAYNE CANCER INSTITUTEHIGHLY ACCURATE AND MINIMALLY MORBIDFOLLOWING LYMPHOSCINTIGRAPHY,

LYMPHATIC MAPPING AND SENTINAL LYMPADENECTOMY (LM/SL) WAS PERFORMED USING BLUE DYE ALONE OR WITH RADIOPHARMACEUTICAL

512 PATIENTS INSTITUTIONAL REVIEW FROM 1985-2000.

THE RATE OF SN POSITIVE WAS 7.1% IN LESIONS BETWEEN 1.01 AND 1.5mm. FOR THE 272 PATIENTS WITH LESIONS < 1.00mm 2.9% WERE SN POSITIVE AND 1.7% OF PATIENTS WITH LESIONS < .75 mm HAD NODAL METS. PATIENTS WITH POSITIVE NODES TENDED TO BE YOUNGER

45

SENTINAL LYMPHADENECTOMY IN CUTANEOUS

THIN MELANOMAS :RICHARD BLEICHER, JOHN WAYNE CANCER INSTITUTE

CONCLUSIONS; LM/SL IS INDICATED IN ALL PRIMARY LESIONS > 1mm AND YOUNG AGE MAY CORRELATE WITH NODAL METS IN LESIONS < 1.0 mm. FOR LESIONS <.75 LM/SL IS RARELY INDICATED, HOWEVER, SHOULD BE CONSIDERED IN NODULAR PRIMARY AND IN YOUNG AGE, (<40 YEARS OLD)

46

CUTANEOUS MELANOMA

CASE STUDIES

47

SUPERFICIAL SPREADING MELANOMA 1.7MM BRESLOW DEPTH

48

WLE WITH RHOMBOID FLAP RECONSTRUCTION

49

FACIAL MELANOMA

SSM- “FIELD OF FIRE”

DISSECTION WITH MUSTARDE FLAP

50

FACIAL MELANOMA

51

INTERMEDIATE DEPTH SSM OF EARLOBE

52

EARLOBE RECONSTRUCTION AND NECK DISSECTION

53

A FARMER FROM IOWA PRESENTS TO OFFICE

54

SIX MONTHS FOLLOWING RADICAL NODE DISSECTION WITH RECURRENCE

55

THERAPEUTIC NODE DISSECTION

56

THERAPEUTIC NODE DISSECTION

IN STAGE 3, PATIENTS WITH ENLARGED NODES HAVE A 85% CHANCE OF HARBORING DISTANT METS AND A SURVIVAL RATE OF <10% AT 10 YEARS.

THE PATIENT SHOWN, DIED 6 MONTHS LATER WITH CHEMOTHERAPY.

57

VISCERAL METASTASES

58

ELECTIVE NODE DISSECTION: PRIOR TO KNOWN NODAL METASTASES

IN STAGE 3 MELANOMA (BY DEFINITION, LIMITED NODAL METS) THE NUMBER OF INVOLVED NODES IS IMPORTANT.

ELND- THE WHO PROSPECTIVE NONRANDOMIZED STUDY

OF 1319 IMPROVED SURVIVAL OF INTERMEDIATE THICKNESS. AT UAB 676 PTS WITH INTERMEDIATE THICKNESS (1.5-4.0) ALSO IMPROVED SURVIVAL.

THERE HAVE BEEN NO RANDOMIZED PROSPECTIVE

TRIALS INDICATING SURVIVAL STATISTICS FOR ELND OF AXIAL MELANOMAS.

THE MAYO CLINIC AND WHO MELANOMA GROUP STUDIES INDICATED NO BENEFIT FROM ROUTINE ELND FOR PATIENTS WITH STAGE1 AND 2 EXTREMITY MELANOMAS

59

HOW IS MELANOMA STAGED ?

STAGING SYSTEM ADOPTED BY THE AMERICAN JOINT COMMITTEE ON CANCERIS BASED ON TUMOR MICROSTAGING OF THE PRIMARY LESION

REGIONAL NODAL BASINS ARE THE MOST LIKELY SITE TO HARBOR SPREAD FOLLOWED BY REGIONAL SKIN (SATELLITOSIS) SUBCUTANEOUS SKIN AND LUNG. COMMON METASTATIC SITES ARE THE LIVER, BRAIN AND BONE.

60

HOW IS MELANOMA STAGED ?

61

HOW IS MELANOMA STAGED ?

62

CUTANEOUS MELANOMA?

ADJUVANT THERAPY

63

ADJUVANT THERAPY IN STAGE 3 AND 4 MELANOMASOMETHING THAT ENHANCES THE EFFECTIVENESS OF MEDICAL THERAPY

CLINICAL BENEFIT OF CYTOTOXIC T LYMPHOCYTES (CTL) CHEMOTHERAPY VACCINES—ALLOGENIC AND AUTOLOGOUS CELLULAR

VACCINES, CARBOHYDRATE VACCINES, DNA VACCINES, PEPTIDE VACCINES AND HEAT-SHOCK PROTEIN VACCINES.

MELANOMA, THE MOST FATAL FORM OF SKIN CANCER, IS RISING AT A RATE FASTER THAN ALL PREVENTABLE CANCERS EXCEPT LUNG CANCER IN THE UNITED STATES. “WE” EVALUATED THE EPA’S SUNWISE SCHOOL PROGRAM FOR SUN SAFETY FOR CHILDREN. RESULTS: STANDARDIZED SUN PROTECTION EDUCATION CAN BE EFFICIENTLY INTERWOVEN INTO SCHOOL HEALTH EDUCATION AND RESULT IN IMPROVEMENTS IN KNOWLEDGE AND POSITIVE INTENTIONS FOR SUN PROTECTION.

MELANOMA INCIDENCE IS RISING 7% PER YEAR

64

ADJUVANT THERAPY IN STAGE 3 AND 4 MELANOMASOMETHING THAT ENHANCES THE EFFECTIVENESS OF MEDICAL THERAPY

VACCINES—ALLOGENIC AND AUTOLOGOUS CELLULAR VACCINES, CARBOHYDRATE VACCINES, DNA VACCINES, PEPTIDE VACCINES AND HEAT-SHOCK PROTEIN VACCINES.

65

ADJUVANT THERAPY IN STAGE 3 AND 4 MELANOMACHEMOTHERAPY; INTERFERON

THERE ARE NO PROVEN TREATMENT REGIMENS THAT SIGNIFICANTLY REDUCE THE LIKELYHOOD OF RECURRENT DISEASE.

IMMUNOTHERAPY- WHILE TOXIC EFFECTS OF HIGH DOSE IL-2 ARE SEVERE, SIG. RESPONSE RATES HAVE BEEN REPORTED.

MONCLONAL ANTIBODY- MONOCLONAL ANTIBODIES ARE TARGETED AS ANTIGENS EXPRESSED ON THE SURFACE OF MELANOMA. THESE ANTIBODIES CAN BE USED TO ACTIVATE THE HOST IMMUNE SYSTEM OR CONJUGATED TO A CYTOTOXIC AGENT.

66

CHEMOTHERAPYCONVENTIONAL CHEMOTHERAPY

(CYTOTOXIC DRUGS) IN THE TREATMENT OF MALIGNANT MELANOMA HAS BEEN DISAPPOINTINGLY INEFFECTIVE.

ONE OF THE MOST EFFECTIVE AGENTS IS DACARBAZIDE. WHY? THE BASIS FOR DRUG RESISTANCE IN MELANOMA IS MOST LIKELY DYSREGULATION OF APOPTOSIS, ALTHOUGH OTHER MECHANISMS SUCH AS DRUG TRANSPORT, DETOXIFICATION AND ENHANCED DNA REPAIR MAY ALSO PLAY A ROLE. AN INHIBITOR OF APOPTOSIS, SURVIVIN, IS EXPRESSED IN MELANOMA AND REQUIRED FOR CELL VIABILITY. TARGETING OF SURVIVIN AND OTHER APOPTOTIC REGULATORS INCREASES THE SENSITIVITY OF MELANOMA CELLS TO CYTOTOXIC DRUGS.

67

MELANOMA CHEMOTHERAPY

CHEMOTHERAPY – FOR PAST 20 YEARS, DICARBAZINE (DTIC) WITH RESPONSE RATES OF < 20%. COMPLETE REMISSION IN < 5% OF PATIENTS. THE COMBINATION OF DTIC, CARMUSTINE, CISPLATIN, AND TAMOXIFEN RESPONSE RATE OF 50% AND A WITH A MEDIAN SURVIVAL OF RERSPONDERS + 10 MONTHS.

68

CUTANEOUS MELANOMA

MOLECULAR AND GENETIC LESIONS UNDERLYING MELANOMA

69

THIS IS THE FUTURE OF MELANOMA TPREVENTION AND TREATMENT:

AS WITH ALL CANCERS WE ARE LOOKING AT THEMOLECULAR BIOLOGY, PATIENT

PHENOTYPE AND CELLULAR MANIPULATION.

70

71

IMPORTANT GENES IN MELANOMA

72

MELANOMA PREVENTION

MELANOMA, THE MOST FATAL FORM OF COMMON SKIN CANCER, IS RISING AT A RATE FASTER THAN ALL PREVENTABLE CANCERS EXCEPT LUNG CANCER IN THE UNITED STATES.

“WE” EVALUATED THE EPA’S SUNWISE SCHOOL PROGRAM FOR SUN SAFETY FOR CHILDREN. RESULTS: STANDARDIZED SUN PROTECTION EDUCATION CAN BE EFFICIENTLY INTERWOVEN INTO SCHOOL BASED EDUCATION PROGRAMS.

TANNING BEDS – ONCOLOGIC AND AESTHETIC NO WIN !

73

CUTANEOUS MELANOMA: QUESTIONS ?

74